Update on psychotropic medication use in renal disease.
Renal failure is a common medical condition, and many patients have comorbid psychiatric disorders. In this review, which is intended as a resource for consultation psychiatrists, the authors discuss pharmacokinetic considerations and provide information about the use of individual psychotropic medications in patients with renal disease. Most psychotropic medications are fat soluble, easily pass the blood-brain barrier, are not dialyzable, are metabolized primarily by the liver, and are excreted mainly in bile. Consequently, the majority of these drugs can be safely used with the end-stage renal disease population.
Cohen
Lewis M
LM
Psychiatri Consultation Service adn Renal Transplantation Service, Baystate Medical Center, Springfield, MA 01199, USA. lewis.cohen@bhs.org
Tessier
Edward G
EG
Germain
Michael J
MJ
Levy
Norman B
NB
D014151:Anti-Anxiety Agents / Q000493:pharmacokinetics; D000928:Antidepressive Agents / Q000493:pharmacokinetics; D014150:Antipsychotic Agents / Q000493:pharmacokinetics; D015897:Comorbidity; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000453:epidemiology; D001523:Mental Disorders / Q000453:epidemiology; D019964:Mood Disorders / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs